Likewise, ADF appears to be ineffective for reducing plasma TNF-α, as two ADF trials in adults with overweight or obesity and metabolic syndrome, which tested changes in TNF-α have not demonstrated significant improvements following ADF regimens [86,91]. The gene discussed is TNF; the disease is obesity due to melanocortin 4 receptor deficiency.